Back to Browse Journals » Clinical Ophthalmology » Volume 2 » Issue 2

Current and emerging therapies for the treatment of age-related macular degeneration

Authors M Vaughn Emerson, Andreas K Lauer

Published Date June 2008 Volume 2008:2(2) Pages 377—388

DOI http://dx.doi.org/10.2147/OPTH.S1485

Published 30 June 2008

M Vaughn Emerson, Andreas K Lauer

Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA

Abstract: Age-related macular degeneration (AMD) is the leading cause of vision loss in the industrialized world. In the last few decades, the mainstay of treatment for choroidal neovascularization (CNV) due to AMD has been thermal laser photocoagulation. In the last decade, photodynamic therapy with verteporfin extended treatment for more patients. While both of these treatments have prevented further vision loss in a subset of patients, improvement in visual acuity is rare. Anti-vascular endothelial growth factor A (VEGF) therapy has revolutionized the treatment of AMD-related CNV. Pegaptanib, an anti-VEGF aptamer prevents vision loss in CNV, although the performance is similar to that of photodynamic therapy. Ranibizumab, an antibody fragment and bevacizumab, a full-length humanized monoclonal antibody against VEGF have both shown promising results with improvements in visual acuity with either agent. VEGF trap, a modified soluble VEGF receptor analogue, binds VEGF more tightly than all other anti-VEGF agents and has also shown promising results in early trials. Other treatment strategies to decrease the effect of VEGF have used small interfering ribonucleic acid (RNA) to inhibit VEGF production and VEGF receptor production. Steroids, including anecortave acetate in the treatment and prevention of CNV, have shown promise in controlled trials. Receptor tyrosine kinase inhibitors, such as vatalanib, inhibit downstream effects of VEGF, and have been effective in the treatment of CNV in early studies. Squalamine lactate inhibits plasma membrane ion channels with downstream effects on VEGF, and has shown promising results with systemic administration. Other growth factors, including pigment epithelium-derived growth factor that has been administered via an adenoviral vector has shown promising initial results. In some patients ciliary neurotrophic factor is currently being studied for the inhibition of progression of geographic atrophy. Combination therapy has been investigated, and may prove to be more effective in the management of AMD-associated CNV. Ongoing and future studies will be crucial for optimizing the treatment of patients with AMD.

Keywords: age related macular degeneration, macular degeneration, VEGF, VEGF antagonist, anti-VEGF, choroidal neovascularization

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Basic training module for vitreoretinal surgery and the Casey Eye Institute Vitrectomy Indices Tool for Skills Assessment

Yeh S, Chan-Kai BT, Lauer AK

Clinical Ophthalmology 2011, 5:1249-1256

Published Date: 1 September 2011

Electroretinographic findings in transplant chorioretinopathy

Brian T Chan-Kai, Steven Yeh, Richard G Weleber, et al

Clinical Ophthalmology 2010, 4:777-783

Published Date: 14 July 2010

Readers of this article also read:

Multifunctional dendrimer-based nanoparticles for in vivo MR/CT dual-modal molecular imaging of breast cancer

Li K, Wen S, Larson AC, Shen M, Zhang Z, Chen Q, Shi X, Zhang G

International Journal of Nanomedicine 2013, 8:2589-2600

Published Date: 19 July 2013

Prevalence of drug resistance and culture-positive rate among microorganisms isolated from patients with ocular infections over a 4-year period

Shimizu Y, Toshida H, Honda R, Matsui A, Ohta T, Asada Y, Murakami A

Clinical Ophthalmology 2013, 7:695-702

Published Date: 9 April 2013

Induction of oxidative stress, DNA damage, and apoptosis in a malignant human skin melanoma cell line after exposure to zinc oxide nanoparticles

Alarifi S, Ali D, Alkahtani S, Verma A, Ahamed M, Ahmed M, Alhadlaq HA

International Journal of Nanomedicine 2013, 8:983-993

Published Date: 7 March 2013

Corrigendum

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

Corrigendum

Nelson DA, Ruf A, Oaknin J, Burgansky-Eliash Z, Barash H, Izhaky D, Loewenstein A, Barak A, Bartov E, Rock T, Grinvald A

Clinical Ophthalmology 2011, 5:1317-1318

Published Date: 15 September 2011

Synthesis and characterization of gold nanorods and their application for photothermal cell damage

Samim M, Prashant CK, Dinda AK, Maitra AN, Arora I

International Journal of Nanomedicine 2011, 6:1825-1831

Published Date: 31 August 2011

Association between dental pulp stones and calcifying nanoparticles

Jinfeng Zeng, Fang Yang, Wei Zhang, et al

International Journal of Nanomedicine 2011, 6:109-118

Published Date: 7 January 2011

Synthesis and characterization of silver/talc nanocomposites using the wet chemical reduction method

Kamyar Shameli, Mansor Bin Ahmad, Wan Zin Wan Yunus, et al

International Journal of Nanomedicine 2010, 5:743-751

Published Date: 29 September 2010

Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials

Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Paolo Verdecchia

Vascular Health and Risk Management 2009, 5:411-427

Published Date: 8 May 2009

Greater osteoblast proliferation on anodized nanotubular titanium upon electrical stimulation

Batur Ercan, Thomas J Webster

International Journal of Nanomedicine 2008, 3:477-485

Published Date: 14 August 2008